Mountain Pacific Investment Advisers Inc. ID Raises Stock Holdings in Catalent Inc (NYSE:CTLT)
Mountain Pacific Investment Advisers Inc. ID boosted its stake in Catalent Inc (NYSE:CTLT) by 128.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 116,876 shares of the company’s stock after buying an additional 65,821 shares during the period. Mountain Pacific Investment Advisers Inc. ID’s holdings in Catalent were worth $6,336,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Janus Henderson Group PLC raised its holdings in Catalent by 17.6% in the 1st quarter. Janus Henderson Group PLC now owns 17,503,223 shares of the company’s stock valued at $710,456,000 after buying an additional 2,620,352 shares during the period. BlackRock Inc. raised its holdings in Catalent by 7.9% in the 1st quarter. BlackRock Inc. now owns 13,918,974 shares of the company’s stock valued at $564,971,000 after buying an additional 1,023,315 shares during the period. Champlain Investment Partners LLC raised its holdings in Catalent by 1.9% in the 1st quarter. Champlain Investment Partners LLC now owns 3,913,500 shares of the company’s stock valued at $158,849,000 after buying an additional 74,670 shares during the period. Norges Bank purchased a new stake in Catalent in the 4th quarter valued at about $47,177,000. Finally, Geode Capital Management LLC increased its stake in Catalent by 8.2% during the fourth quarter. Geode Capital Management LLC now owns 1,422,860 shares of the company’s stock worth $44,364,000 after purchasing an additional 108,407 shares during the period. Hedge funds and other institutional investors own 96.85% of the company’s stock.
In other news, insider Barry Littlejohns sold 15,940 shares of the business’s stock in a transaction dated Friday, July 12th. The stock was sold at an average price of $53.53, for a total transaction of $853,268.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Donald E. Morel, Jr. acquired 10,000 shares of the stock in a transaction dated Wednesday, May 15th. The shares were bought at an average cost of $44.44 per share, with a total value of $444,400.00. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 56,500 shares of company stock valued at $2,542,845. Corporate insiders own 1.40% of the company’s stock.
NYSE:CTLT traded down $0.80 on Monday, reaching $56.46. 4,722 shares of the company’s stock were exchanged, compared to its average volume of 593,456. The company has a quick ratio of 1.71, a current ratio of 2.18 and a debt-to-equity ratio of 1.31. The stock has a market cap of $8.34 billion, a price-to-earnings ratio of 35.53, a price-to-earnings-growth ratio of 2.81 and a beta of 1.64. The business has a fifty day simple moving average of $53.03. Catalent Inc has a 52-week low of $29.23 and a 52-week high of $57.45.
Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.42 by $0.07. The company had revenue of $617.50 million for the quarter, compared to analyst estimates of $644.88 million. Catalent had a net margin of 6.01% and a return on equity of 16.78%. The business’s revenue for the quarter was down 1.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.41 earnings per share. As a group, research analysts anticipate that Catalent Inc will post 1.71 EPS for the current year.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Article: Strangles
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.